— Know what they know.
Not Investment Advice
Also trades as: 0J8P.L (LSE) · $vol 1M

IDXX NASDAQ

IDEXX Laboratories, Inc.
1W: +0.6% 1M: +6.1% 3M: -1.5% YTD: -16.2% 1Y: -12.4% 3Y: +31.4% 5Y: -12.4%
$561.25
-8.96 (-1.57%)
Pre-Market: $509.00 (-52.25, -9.31%)
Weekly Expected Move ±3.6%
$520 $540 $560 $581 $601
NASDAQ · Healthcare · Medical - Diagnostics & Research · Tech Score Buy · Power 78 · $44.2B mcap · 78M float · 0.746% daily turnover · Short 53% of daily vol
Credit Risk of going bust: lower than 88% of companies Debt: 2.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.50 (down 99.7%), IDEXX Laboratories, Inc. would be worth roughly what it owes.
Total debt $1.10B against a stock market value of $44.22B.
Distance to default 12.75 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $818.9M (short-term plus half of long-term), stock volatility 31.9%; Altman Z'' 10.84. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$3.4B +1.7% ▲
5Y CAGR: +7.9%
Total Liabilities
$1.7B +2.8% ▲
5Y CAGR: +1.0%
Shareholders Equity
$1.6B +0.6% ▲
5Y CAGR: +20.5%
Cash & Investments
$180M -37.5% ▼
5Y CAGR: -14.1%
Total Debt
$1.1B +9.1% ▲
5Y CAGR: +1.4%
Net Debt
$897M +28.4% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$144M$113M$454M$288M$180M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$144M$113M$454M$288M$180M
Net Receivables$426M$491M$530M$561M$693M
Inventory$269M$368M$380M$382M$378M
Other Current Assets$75M$88M$83M$110M$31M
Total Current Assets$956M$1.1B$1.5B$1.4B$1.3B
Property, Plant & Equip.$693M$768M$818M$829M$871M
Goodwill & Intangibles$458M$459M$450M$517M$524M
Long-Term Investments$19M$56M$56M$58M$297M
Other Non-Current Assets$287M$307M$333M$364M$291M
Total Non-Current Assets$1.5B$1.6B$1.8B$1.9B$2.0B
Total Assets$2.4B$2.7B$3.3B$3.3B$3.4B
— Liabilities —
Accounts Payable$116M$110M$111M$114M$110M
Short-Term Debt$148M$654M$325M$418M$500M
Deferred Revenue$40M$38M$37M$34M$35M
Other Current Liabilities$183M$143M$174M$175M$202M
Total Current Liabilities$764M$1.2B$952M$1.1B$1.1B
Long-Term Debt$775M$694M$623M$450M$476M
Other Non-Current Liab.$71M$68M$66M$44M-$45M
Total Non-Current Liabilities$984M$902M$824M$630M$597M
Total Liabilities$1.7B$2.1B$1.8B$1.7B$1.7B
— Equity —
Common Stock$11M$11M$11M$11M$11M
Retained Earnings$2.9B$3.6B$4.4B$5.3B$6.4B
Accumulated OCI-$53M-$78M-$71M-$94M-$63M
Total Stockholders Equity$690M$609M$1.5B$1.6B$1.6B
Total Liabilities & Equity$2.4B$2.7B$3.3B$3.3B$3.4B
— Key Metrics —
Total Debt$1.0B$1.5B$1.1B$987M$1.1B
Net Debt$887M$1.4B$613M$699M$897M
Total Investments$19M$56M$56M$58M$297M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms